Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

PURPOSE: To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer. PATIENTS AND METHODS: The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicenter trial. Pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, Matthew J., Llombart-Cussac, Antonio, Feltl, David, Dewar, John A., Jasiówka, Marek, Hewson, Nicola, Rukazenkov, Yuri, Robertson, John F.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2015
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737861/
https://www.ncbi.nlm.nih.gov/pubmed/26371134
http://dx.doi.org/10.1200/JCO.2015.61.5831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737861/
https://www.ncbi.nlm.nih.gov/pubmed/26371134
http://dx.doi.org/10.1200/JCO.2015.61.5831

Ejemplares similares